Tuesday, October 13, 2026

Cocoa Bearish Momentum: 0.98% Down Since The Last Session

ViaNews Editorial Team

January 22, 2021

Cocoa Bearish Momentum: 0.98% Down Since The Last Session

Cocoa is currently on bearish momentum. At 13:15 EST on Friday, 22 January, Cocoa is at $2,525.00 and 0.98% down since the last session's close.

Cocoa Range

Cocoa is 0.473% down from its last session low of $2,537.00 and 1.866% down from its last session high of $2,573.00.

Cocoa is 3.77% down from its last three sessions higher value of $2,624.00 and is 0.16% up from its last three sessions lower value of $2,521.00.

Cocoa is 3.77% down from its last seven sessions higher value of $2,624.00 and is 2.52% up from its last seven sessions lower value of $2,463.00.

Cocoa is 5.11% down from its last month's higher value of $2,661.00 and is 3.53% up from its last month's lower value of $2,439.00.

Volatility

Cocoa's last day, last week, and last month's average volatility was a negative 0.75%, a positive 0.58%, and a positive 0.15%, respectively.

Cocoa's last day, last week, and last month's high and low average amplitude percentage was 1.42%, 2.30%, and 2.72%, respectively.

Last news about Cocoa

Chocolate war leaves world’s top cocoa producer stuck with beans. According to Bloomberg Quint on Wednesday, 20 January, "The average West African grower farms no more than 3.5 hectares and supports six to eight family members, according to the World Cocoa Foundation industry group. ", "The strategy, recounted in the book "La Guerre du Cacao," or "The Cocoa War," backfired, and prices more than halved during the 18-month ban."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com